Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose
cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …

Background The cardiovascular safety and efficacy of many current antihyperglycemic agents,
including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. Methods We …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …

Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …

Background In observational analyses, higher levels of high-density lipoprotein (HDL)
cholesterol have been associated with a lower risk of coronary heart disease events. However, …

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence
and/or discontinuation, contributing to adverse cardiovascular outcomes. This …

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure or death from cardiovascular causes among patients with stable heart …